Anti-TINAG/ TIN-AG functional antibody
Anti-TINAG/ TIN-AG functional antibody for cell culture, ELISA & in-vivo assay
Go to TINAG/TINAG products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
Catalog No. | Product Name | Species Reactivity |
---|---|---|
GM-Tg-hg-SE1341-Ab-1/ GM-Tg-hg-SE1341-Ab-2 | Anti-Human TINAG monoclonal antibody | Human |
GM-Tg-rg-SE1341-Ab-1/ GM-Tg-rg-SE1341-Ab-2 | Anti-Rat TINAG monoclonal antibody | Rat |
GM-Tg-mg-SE1341-Ab-1/ GM-Tg-mg-SE1341-Ab-2 | Anti-Mouse TINAG monoclonal antibody | Mouse |
GM-Tg-cynog-SE1341-Ab-1/ GM-Tg-cynog-SE1341-Ab-2 | Anti-Cynomolgus/ Rhesus macaque TINAG monoclonal antibody | Cynomolgus/ Rhesus macaque |
GM-Tg-felg-SE1341-Ab-1/ GM-Tg-felg-SE1341-Ab-2 | Anti-Feline TINAG monoclonal antibody | Feline |
GM-Tg-cang-SE1341-Ab-1/ GM-Tg-cang-SE1341-Ab-2 | Anti-Canine TINAG monoclonal antibody | Canine |
GM-Tg-bovg-SE1341-Ab-1/ GM-Tg-bovg-SE1341-Ab-2 | Anti-Bovine TINAG monoclonal antibody | Bovine |
GM-Tg-equg-SE1341-Ab-1/ GM-Tg-equg-SE1341-Ab-2 | Anti-Equine TINAG monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
Catalog No. | GM-Tg-hg-SE1341-Ab-1/ GM-Tg-hg-SE1341-Ab-2; GM-Tg-rg-SE1341-Ab-1/ GM-Tg-rg-SE1341-Ab-2; GM-Tg-mg-SE1341-Ab-1/ GM-Tg-mg-SE1341-Ab-2; GM-Tg-cynog-SE1341-Ab-1/ GM-Tg-cynog-SE1341-Ab-2; GM-Tg-felg-SE1341-Ab-1/ GM-Tg-felg-SE1341-Ab-2; GM-Tg-cang-SE1341-Ab-1/ GM-Tg-cang-SE1341-Ab-2; GM-Tg-bovg-SE1341-Ab-1/ GM-Tg-bovg-SE1341-Ab-2; GM-Tg-equg-SE1341-Ab-1/ GM-Tg-equg-SE1341-Ab-2 |
Products Name | Anti-TINAG monoclonal antibody |
Format | mab |
Target Name | TINAG |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category of antibody | FACS/Biofunctional Antibody |
Derivation (species) | Mouse |
CH1+2+3 Isotype (Receptor identification) | IgG |
Type of Light Chain (VD-LC) | N/A |
Expression platform | Mammalian Expression |
Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD). |
Tag | Fc |
Products description | Pre-made anti-TINAG benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
Category | Cat No. | Products Name |
Target Antigen | GM-Tg-g-SE1341-Ag-1 | Recombinant multi-species TINAG/ TIN-AG protein |
Target information
Target ID | GM-SE1341 |
Target Name | TINAG |
Gene ID | 27283,26944,300846,711185,481848,101087743,512517,100069589 |
Gene Symbol and Synonyms | TIN-AG,TINAG |
Uniprot Accession | Q9UJW2,Q3SZI1 |
Uniprot Entry Name | TINAG_HUMAN,TINAG_BOVIN |
Protein Sub-location | Secreted Protein/Potential Cytokines |
Category | |
Disease | N/A |
Gene Ensembl | ENSG00000137251 |
Target Classification | N/A |
The target: TINAG, gene name: TINAG, also named as TIN-AG. This gene encodes a glycoprotein that is restricted within the kidney to the basement membranes underlying the epithelium of Bowman's capsule and proximal and distal tubules. Autoantibodies against this protein are found in sera of patients with tubulointerstital nephritis, membranous nephropathy and anti-glomerular basement membrane nephritis. Ontogeny studies suggest that the expression of this antigen is developmentally regulated in a precise spatial and temporal pattern throughout nephrogenesis. [provided by RefSeq, Nov 2011].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.